Telomir Pharmaceuticals, Inc. Common Stock
TELO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $760 | $43 | $337 | $269 |
| G&A Expenses | $0 | $5,027 | $0 | $0 |
| SG&A Expenses | $387 | $5,027 | $1,851 | $2,636 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,146 | $5,070 | $2,188 | $2,905 |
| Operating Income | -$1,146 | -$5,070 | -$2,188 | -$2,905 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $44 | $0 | $8 | $7 |
| Pre-Tax Income | -$1,102 | -$5,070 | -$2,180 | -$2,898 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,102 | -$5,070 | -$2,180 | -$2,898 |
| % Margin | – | – | – | – |
| EPS | -0.034 | -0.17 | -0.073 | -0.098 |
| % Growth | 80% | -132.2% | 25.3% | – |
| EPS Diluted | -0.034 | -0.17 | -0.073 | -0.098 |
| Weighted Avg Shares Out | 31,040 | 30,010 | 29,763 | 29,539 |
| Weighted Avg Shares Out Dil | 31,040 | 30,010 | 29,763 | 29,539 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44 | $1 | $8 | $7 |
| Interest Expense | $3 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1,100 | -$5,069 | -$2,180 | -$2,898 |
| % Margin | – | – | – | – |